Efficacy of platelet-rich plasma injection in combination with tranexamic acid compared with tranexamic acid injection alone inthe treatment of macular amyloidosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220808055641N4

Enrollment

Registered

2024-02-03

Start date

2024-02-09

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular amyloidosis. Other amyloidosis

Interventions

Intervention 1: Intervention group:injection of tranexamic acid in combination with platelet rich plasma and evaluation in 4 weeks, 8 weeks and 12 weeks. Intervention 2: Control group: injection of tr

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis of macular amyloidosis Age above 18 years old

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Coagulation disorders

Design outcomes

Primary

Measure	Time frame
Improvement of macular amyloidosis. Timepoint: The beginning of the study and 1 month after the start of the study and 3 months after the start of the study. Method of measurement: sonography;visioface;biometery;cutometery,physician global assessment score;patient global assessment score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Jafarzadeh

Iran University of Medical Sciences

alirezajafarzadeh8@gmail.com+98 919 890 7445

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026